Protective effect of CpG-DNA against mastitis induced by Escherichia coli infection in a rat model.
A mastitis model in rats, induced by Escherichia coli infection, was established and the protective effect of Cytosine-phosphate-Guanosine (CpG)-DNA was determined. An E. coli suspension containing either 2 x 10(3) colony forming units (CFU)mL(-1)(EL group), 2 x 10(5)CFU mL(-1) (EH group), or (as controls) 100 microL phosphate buffer saline (CON group), was inoculated into the mammary glands 72 h after parturition. The rats were euthanased 24 h post-infection. The histopathological changes in mammary tissue in the EL group were mild, whereas the structural changes in the EH group were severe and polymorphonuclear leukocytes (PMNs) had accumulated in the mammary alveoli. Interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha and N-acetyl-beta-d-glucosaminidase (NAGase) were significantly increased in the mammary tissue from the EH group but not significantly changed in the EL group. On the basis of these findings, the potential protective effect of CpG-DNA on mammary glands was tested using a 2 x 10(5)CFU mL(-1) suspension. An intramuscular injection of either CpG-DNA (200 microg) or PBS (100 microL) was given immediately after parturition. At 72 h post-partum, 2 x 10(5)CFU mL(-1)E. coli (100 microL) were inoculated into the mammary glands of all rats. At pre-infection (0 h), and 8, 16, 24, 48 and 72 h after inoculation six rats were euthanased. CpG-DNA induced more rapid migration of PMNs from the blood to mammary tissue at the initial stage of infection, stimulated the secretion of IL-6 and TNF-alpha at different time points, reduced viable E. coli in mammary tissues and decreased the activity of NAGase. CpG-DNA also promoted the expression of its specific receptor TLR-9 mRNA in mammary tissue. The study showed that CpG-DNA protected against E. coli mastitis in this rat model.
Zhu
Yumin
Y
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, PR China.
Fan
Hongjie
H
Miao
Jinfeng
J
Zou
Sixiang
S
D000118:Acetylglucosaminidase / Q000096:biosynthesis; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D015850:Interleukin-6 / Q000096:biosynthesis; D008297:Male; D008321:Mammary Glands, Animal / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D008413:Mastitis / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D015850:Interleukin-6; D009838:Oligodeoxyribonucleotides; D014409:Tumor Necrosis Factor-alpha; D000118:Acetylglucosaminidase